Searchable abstracts of presentations at key conferences in endocrinology

ea0026p225 | Pituitary | ECE2011

Effect of GH as add-on treatment in severe fibromyalgia syndrome. Results from the IIIb, CT27560 placebo-controlled, multicenter trial

Cuatrecasas Guillem , Alegre Cayetano , Sola Joaquim Fernandez , Gonzalez Maria Jose , Lage Mary , Sesmilo Gemma , Granados Enrique , Domingo Manuel Puig

Introduction: Functional GH deficiency has been described in fibromyalgia (FM). The efficacy of GH as add-on treatment has been suggested in small studies, but little is known in larger and homogeneous populations.Design: Patients (120) were enrolled in a multicenter, randomized, placebo-controlled trial for 18 months (NCT00933686). FM impact questionnaire (FIQ) >75 (severe), duration of FM >18 months, and stability of the standard therapy (amitr...

ea0070aep331 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Clinical and metabolic benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) therapy in diabetic patients with psychiatric comorbidities

Concepción Terroba-Larumbe María , Crespo-Soto Cristina , Palacio-Mures Jose Maria , Gonzalez-Sagrado Manuel , Conde-Vicente Rosa , Ventosa-Viña Marta , Peña-Lozano Silvia , Portela-Martin Ainara , Fernandez-Nuñez Marta , Calleja-Barnada Mar , Cuellar-Olmedo Luis

Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) therapyhas proven effective in type 2 diabetes but there is little data on its effect in patients with psychiatric comorbidity, who usually present worse metabolic and clinical control. The aim of this study was to evaluate if there are differences in the effect of this therapy in relation to the presence of these pathologies.Methods: 225 patients included in a therapy protocol with SGLT2i,...